怀伯恩-梅森综合征中的黄斑水肿：玻璃体腔内注射抗VEGF治疗后消退。病例报告及文献综述
Macular edema in Wyburn-Mason syndrome: Resolution with anti-VEGF intravitreal injections. Case report and review of the literature.
作者信息
Hupin Nathan, Cahill Thomas, Boschi Antonella, Kozyreff Alexandra
机构信息
Department of Ophthalmology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
VisIoNS, Institute of NeuroScience, Université Catholique de Louvain, Brussels, Belgium.
出版信息
Am J Ophthalmol Case Rep. 2024 Oct 30;36:102209. doi: 10.1016/j.ajoc.2024.102209. eCollection 2024 Dec.
PURPOSE
Macular edema is an infrequent complication of retinal arteriovenous malformations. We present the management of unilateral macular edema with Bevacizumab 1.25mg/0.05mL and Aflibercept 2mg/0.05mL in a 16-year-old child with Wyburn-Mason syndrome.
OBSERVATIONS
The patient developed macular edema after 15 years of unremarkable ophthalmological follow-up. After a one-month observation period, a first intravitreal injection of Bevacizumab 1.25mg/0.05mL, the treatment most frequently described in the literature, was found to be insufficient to reduce the macular edema.After the switch to Aflibercept 2.0mg/0.05mL, a significant reduction in macular edema was observed after three monthly intravitreal injections. This effect was prolonged over the 15-month observation follow-up.
CONCLUSIONS AND IMPORTANCE
Aflibercept 2mg/0.05mL may be a safe and effective option to manage macular edema complications in retinal arteriovenous malformations.
目的
黄斑水肿是视网膜动静脉畸形的一种罕见并发症。我们介绍了一名患有怀伯恩 - 梅森综合征的16岁儿童单侧黄斑水肿采用贝伐单抗1.25mg/0.05mL和阿柏西普2mg/0.05mL的治疗情况。
观察结果
该患者在15年眼科随访无异常后出现黄斑水肿。经过一个月的观察期后，首次玻璃体内注射文献中最常描述的治疗药物贝伐单抗1.25mg/0.05mL，发现不足以减轻黄斑水肿。改用阿柏西普2.0mg/0.05mL后，在每月一次的三次玻璃体内注射后观察到黄斑水肿显著减轻。这种效果在15个月的观察随访期内持续存在。
结论与意义
阿柏西普2mg/0.05mL可能是治疗视网膜动静脉畸形黄斑水肿并发症的一种安全有效的选择。
Zotero 插件